STAT3 overexpression are still in the clinical research stage. In this study, a series of 2,6-disubstituted purine derivatives were designed and synthesized, and their biological activities, as small molecule inhibitors of STAT3, were assessed. Compound PD26-TL07 exhibited remarkable antiproliferative activity against three cancer cell lines (IC50 values for HCT-116, SW480 and MDA-MB-231 were 1.77 ± 0
STAT3的持续活化与癌症的发展密切相关,但STAT3过表达的
抑制剂仍处于临床研究阶段。在这项研究中,设计和合成了一系列的2,6-二取代
嘌呤衍
生物,并评估了它们作为STAT3的小分子
抑制剂的
生物学活性。化合物PD26-TL07对三种癌细胞显示出显着的抗增殖活性(HCT-116,SW480和
MDA-MB-231的IC 50值分别为1.77±0.35、1.51±0.19和1.25±0.38μM)。此外,详细的
生物学分析表明,PD26-TL07可以有效抑制STAT3
磷酸化,而对他人的抑制却很小。新发现的PD26-TL07在体外和体内均显示出预期的抗癌作用。分子对接模型揭示PD26-TL07可以结合STAT3的SH2结构域。三种其他化合物(PD26-
BZ01,PD26-TL03和PD26-AS06)也能够抑制这种
磷酸化。这项研究描述了新型2,6-二取代
嘌呤衍
生物作为针对STAT3的有效抗癌药。